Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Uveitis Treatment market is witnessing an increase pushed with the aid of a worldwide upward thrust within the incidence of uveitis, an inflammatory eye situation affecting the uvea. Factors including infections, autoimmune sicknesses, and environmental elements contribute to the growing prevalence, creating a demand for powerful remedy options. Corticosteroids, both topical and systemic, continue to be widely used in the Uveitis Treatment marketplace for their anti-inflammatory residences. Ongoing studies aim to increase sustained-release formulations to beautify the length of movement and limit the need for common administration. Research and improvement efforts are exploring novel pathways involved in uveitis, leading to the emergence of cures focused on particular molecular and mobile mechanisms. This diversification of treatment options aims to cope with one-of-a-kind subtypes and causes of uveitis.
There is a growing emphasis on early diagnosis and intervention in the Uveitis Treatment panorama. Timely recognition and remedy of uveitis are vital to save you from complications and enhance average patient results, using the marketplace in the direction of faster-appearing and more targeted remedies. Combination treatments involving the use of multiple drugs with complementary mechanisms of motion are gaining attention in the Uveitis Treatment market. This method aims to obtain synergistic results, enhance treatment efficacy, and probably lessen the reliance on high-dose monotherapies. The marketplace is increasingly adopting patient-centric techniques, thinking about elements such as treatment comfort, reduced facet outcomes, and stepping forward to the best of lifestyles. Drug delivery improvements, which include sustained-launch formulations and localized management, align with this affected person-centric focus.
Advancements in imaging technologies play a sizable role in uretic treatment. High-decision imaging modalities are useful resources for determining the correct prognosis and tracking and evaluating treatment reactions, contributing to more customized and powerful healing techniques. The Uveitis Treatment market is witnessing regulatory approvals for brand-spanking new remedies, facilitating market expansion. Approval of novel pills and biologics enhances the treatment armamentarium, offering healthcare specialists extra alternatives for handling uveitis. Despite improvements, demanding situations associated with the accessibility and affordability of certain Uveitis Treatments persist. Efforts to address these demanding situations, including the development of conventional alternatives and elevated focus, are essential for broader marketplace attainment. Collaborations between pharmaceutical businesses, studies establishments, and healthcare businesses are using research projects and medical trials within the Uveitis Treatment market.
Uveitis Treatment Market Highlights:
Global Uveitis Treatment Market Overview
The Uveitis Treatment Market Size was valued at USD 0.66 Billion in 2023. The Global Uveitis Treatment industry is projected to grow from USD 0.70 Billion in 2024 to USD 1.14 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.98% during the forecast period (2024 - 2032). Uveitis is a form of inflammation that occurs in the middle layer of the eyeball known as the uvea. It is accompanied by symptoms such as pain, redness of the eyes, and blurred vision. It mainly occurs in people aged between 20 to 50 years. There are three main types of uveitis anterior uveitis, posterior uveitis, and intermediate uveitis.
For instance, in June 2016, AbbVie Inc received FDA (Food and Drug Administration) approvals for its HUMIRA in the treatment of non-infectious intermediate, posterior, and panuveitis. This helped it to strengthen its uveitis treatment product portfolio.
A key factor propelling the uveitis treatment market is the worldwide increase in uveitis incidence and prevalence. The increased incidence of uveitis can be attributed to a number of factors, including autoimmune illnesses, infections, and inflammatory disorders. Moreover, the therapy of uveitis has also been progressed thanks to the discovery of new drugs such biologic treatments, immunosuppressants, and targeted medicines.
The development of more precise and efficient methods of treatment is a major factor driving the market forward. Therefore, the early diagnosis and quick treatment of uveitis have resulted from rising awareness about the condition among healthcare professionals and patients. As a result, there is a greater need for effective treatments for uveitis.
Rapid market expansion may be attributed, in part, to the increase in spending on research projects in the ophthalmology sector. Refractory posterior or intermediate uveitis are the subject of a growing number of clinical trials across the world. Several randomized, controlled trials of alternative treatments to the conventional corticosteroid therapy for noninfectious uveitis, such as mycophenolate mofetil and methotrexate, are currently enrolling patients.
Moreover, the improvement of therapy choices for ocular inflammatory problems is largely attributable to the creation of biological therapies through intensive R&D efforts. As a result, this is increasing the need for these medications and stimulating the market.
In April 2024, Roivant declared a share repurchase scheme of $1.5 billion, which included purchasing Sumitomo Pharma's complete shareholding for $648 million. In conjunction with the announcement of the repurchase, Priovant Therapeutics, a collaboration between Roivant and Pfizer, disclosed that the investigational medication brepocitinib shown efficacy in alleviating symptoms of non-infectious uveitis in a phase II trial. The NEPTUNE trial, which included 26 patients, assessed treatment failure as the primary endpoint at 24 weeks. The trial aimed to determine the extent of effect by measuring lower rates of treatment failure. The data indicate that 29% of participants who were given a dose of 45mg of brepocitinib reported treatment failure after 24 weeks, while the same was true for 44% of participants in the 15mg group. In contrast, a previous trial of AbbVie's Humira (adalimumab), which is now the only licensed medication that targets the cause of non-infectious uveitis, had a failure rate of 62%. However, the drug lost important patents last year.
In October 2023, ANI Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration (FDA) has granted permission for the commercial distribution of a 1-mL vial containing 80 USP units/1 mL of Purified Cortrophin® Gel (repository corticotropin injection USP), also known as Cortrophin Gel. The 1-mL vial of Cortrophin Gel can now be obtained through the existing specialty pharmacy network and can also be ordered through national specialty distributors.
May 2023:The Israeli firm BioNanoSim will partner with the Greek manufacturer RAFARM to launch BNS Ophthalmics (BNSO), which will sell pharmaceuticals designed by BNS to treat critical eye illnesses. The company's flagship product, BNSO-1, is a topically applied anti-inflammatory drug. Chronic Anterior Uveitis is an inflammation of the iris that can be caused by a number of infectious and noninfectious disorders. By the end of the year, BNSO plans to begin a clinical research employing the innovative medication in patients with this condition.
Uveitis Treatment Market Trends
Rising prevalence of uveitis, increasing R&D expenditure, and product launches are likely to impact the growth of the uveitis treatment market positively.
Market Drivers
Increased R&D expenditure in the healthcare industry will support the growth of the uveitis treatment market.
The growth of the market is driven by the increasing number of product launches in the uveitis treatment market. For example, in October 2018, EyePoint Pharmaceuticals received FDA approval for Yutiq (fluocinolone acetonide intravitreal implant). This product is used in the treatment of chronic non-infectious uveitis.
Increasing prevalence of the uveitis across the globe
Market Restraints
Side-effect related to corticosteroid drugs is likely to hamper the growth of the uveitis treatment market during the forecast period
Uveitis Treatment Market Segment Insights
Uveitis Treatment Type Insights
Anterior Uveitis: In anterior uveitis, inflammation forms in the middle layer of the eye that includes the iris and adjacent tissue. This segment holds the most significant share in the type segment. Mainly topical drops such as corticosteroid drops are prescribed by the physician in the treatment of the anterior uveitis.
Intermediate Uveitis: It occurs in children as well as young adults. It accounts for 2% 31% of all uveitis patients and incidence of the intermediate uveitis between 1.4% to 2% in Germany.
Posterior Uveitis: In posterior uveitis, the inflammation primarily forms in the retina and choroid area of the eye.
Others
Uveitis Treatment Drug Class Insights
Corticosteroids Drugs: This drug class is most commonly used for the treatment of uveitis. It expected to hold the largest share in the uveitis treatment market due to the increasing preference of this drug class and desirable outcomes. Major corticosteroid brands in the uveitis treatment market are Ozurdex (Allergan PLC) and Triesence suspension (Novartis AG).
Anti-Inflammatory Drugs: In chronic uveitis, non-steroid anti-inflammatory drugs are used to treat inflammation over a more extended period.
Immunosuppressive Drugs: Maximum immunosuppressive agents have significant adverse effects due to which these drugs are not used very often for the treatment of the uveitis.
Uveitis Treatment End-User Insights
Hospitals: The largest segment, hospitals are usually the primary points for diagnosis, treatment, and rehabilitation of individuals. In 2018, the hospital's segment held the largest share of the uveitis treatment market.
Specialty Clinics: Consisting of long-term care for chronic patients and the elderly, this is a fast-growing market segment, especially in developed nations.
Others
January 2023:Active Biotech reported that their phase I clinical research of an eye drop formulation of laquinimod in healthy participants had been successfully completed. Inflammatory eye illnesses, such as non-infectious uveitis, a sight-threatening eye condition, have an unmet medical need for more therapeutic therapies with a favorable safety and tolerability profile. No safety problems or local toxicity issues were found with the dose regimens examined for the laquinimod eye drop in this trial, which is a promising sign.
August 2023:A local ocular delivery patent for the KIO-100 family of non-steroidal anti-inflammatory small compounds was issued in the United States (Patent No. 11,730,716) and Europe in August 2023, as reported by Kiora Pharmaceuticals, Inc. In addition to protecting Kiora's pipeline, this IP also extends market exclusivity for approved indications in the United States and Europe for a number of inflammatory-related therapeutic applications, such as the treatment of posterior non-infectious uveitis.
Uveitis Treatment Regional Insights
Americas:The Americas held the largest regional uveitis treatment market in 2018. The US has over 7,200 active hospitals and a well-established healthcare sector. This serves to drive development in the region's market for uveitis treatment.
Additionally, increasing the incidence of uveitis in the US is likely to support the growth of the uveitis treatment market. The annual rate of uveitis around 26.6 to 102 per 100,000 adults in the US. Moreover, uveitis has led to about 2.8% of cases of blindness in the US.
Europe: The need for uveitis treatment is high in this region due to the rising prevalence of the uveitis in the region.
Asia-Pacific: The Asia-Pacific is the fastest-growing region for the uveitis treatment market. It has the world’s largest population and a fast-developing healthcare sector.
Middle East & Africa: It is projected to account for the least share of the uveitis treatment market due to low per capita disposable incomes in the region and limited development of healthcare facilities.
Additionally, increasing the incidence of uveitis in the US is likely to support the growth of the uveitis treatment market. The annual rate of uveitis around 26.6 to 102 per 100,000 adults in the US. Moreover, uveitis has led to about 2.8% of cases of blindness in the US.
Europe: The need for uveitis treatment is high in this region due to the rising prevalence of the uveitis in the region.
Asia-Pacific: The Asia-Pacific is the fastest-growing region for the uveitis treatment market. It has the world’s largest population and a fast-developing healthcare sector.
Middle East & Africa: It is projected to account for the least share of the uveitis treatment market due to low per capita disposable incomes in the region and limited development of healthcare facilities.
Uveitis Treatment Market Key Players
- Allergan PLC (Ireland)
- Bausch Health (Canada)
- Novartis AG (Switzerland)
- EyePoint Pharmaceuticals, Inc. (US)
- AbbVie Inc. (US)
- Horizon Therapeutics Plc (Ireland)
- Mylan NV (US)
- Alimera Sciences (US)
- Others
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
